- Also Known As:
- Iron Overload Disease
- Iron Storage Disease
What is hemochromatosis?
Hemochromatosis is an iron metabolism disorder that may be inherited or acquired. People with hemochromatosis accumulate more iron than their body needs. As the body does not have a way to excrete excess iron, there is a progressive buildup of iron in tissues and organs.
Eventually, the iron overload can lead to dysfunction and failure of several organs, notably the heart, liver, and endocrine portion of the pancreas. Complications include arthritis, diabetes, liver cirrhosis, heart arrhythmias and heart failure, and an increase in skin pigmentation called “bronzing.”
There are two types of hemochromatosis: primary hemochromatosis, an inherited form that is passed from one generation to the next, and secondary hemochromatosis, which is caused by some other disease or underlying condition.
Primary or Hereditary Hemochromatosis (HH)
Hereditary hemochromatosis (HH), also called primary hemochromatosis, is one of the most common genetic disorders in the U.S., affecting about one million people, most of them Caucasians. The disease is usually caused by a mutation in the HFE gene. Everyone has two copies of the HFE gene – one inherited from their mother and one inherited from their father.
The mutations lead to changes in amino acids, the building blocks of proteins, and they are commonly referred to by the changes they induce in these amino acids. For example, the most common mutation involves changing from an amino acid called cysteine (C) to one called tyrosine (Y) in the 282nd amino acid of the protein made by the HFE gene; this mutation is called C282Y.
There are several mutations in the HFE gene that can cause hemochromatosis. The probability of developing iron overload depends on the combination of genes inherited.
See below for more details on the HFE gene.
Secondary or Acquired Hemochromatosis
Secondary hemochromatosis is an acquired iron overload that can be due to a variety of other diseases and conditions. Examples include:
Signs and Symptom
According to the National Heart, Lung and Blood Institute, not everyone who has hemochromatosis will have signs and symptoms, and though estimates vary, as many as half of those with the disease may not have any initial symptoms. Signs and symptoms tend to emerge and increase in severity over a long period of time and can be similar to those of other conditions.
Typically, men will not become symptomatic until they are 40-60 years old. Most women with hemochromatosis will not experience symptoms until several years after their menstrual periods stop due to menopause (around age 50).
Signs and symptoms will vary from person to person and may include:
- Fatigue, weakness
- Abdominal pain
- Joint pain
- Increased blood glucose levels and diabetes
- Liver dysfunction and/or abnormal liver blood tests
- Decreased sex drive, erectile dysfunction in men
- Lack of menstruation in women
- Low thyroid hormone (hypothyroidism)
- Changes in skin color, turning grey or bronze
The tests below are used to detect and diagnose hemochromatosis and evaluate body organs for the severity of iron overload. They may also be used to monitor the effectiveness of treatment. Genetic testing may be used to confirm a diagnosis, but since many people who have genetic mutations associated with the disease never develop symptoms, blood tests are considered the most reliable form of diagnosis.
Laboratory testing typically includes:
- Serum iron — used to check iron levels in the blood
- Total iron-binding capacity (TIBC) — measures the total amount of iron that can be bound by proteins in the blood; transferrin is the primary iron-binding protein and the TIBC test is a good indirect measurement of transferrin availability.
- Transferrin saturation — a calculation using the iron and TIBC test results, representing the percentage of the transferrin that is saturated with iron; it is elevated with hereditary hemochromatosis (HH) but is not specific for it.
- Ferritin — used to evaluate the body’s iron stores; it may be elevated with HH but is not specific for it. In those who have HH gene mutations, normal levels mean low risk for developing organ damage.
- Liver panel — a group of tests used to evaluate liver function
- Genetic testing — can be used to help confirm a diagnosis of HH. Most cases of HH, about 80-90%, are caused by two copies of a C282Y mutation in the HFE gene. The presence of two copies of the C282Y mutation does not necessarily mean that a person will develop the disorder but does indicate an increased risk, and men are more likely to be affected than women. The largest population study found about a 25% risk among men and 1% risk among women. Sometimes two copies of H63D or S65C mutations of the HFE gene or paired combinations of the three may cause HH. Rarely, the condition may be due to another genetic abnormality.
- Liver biopsy — while it is usually not necessary to confirm the diagnosis by examination of a liver biopsy specimen for iron accumulation, a biopsy is often done to help determine the extent of liver damage.
An MRI (magnetic resonance imaging) test may be used to help evaluate the amount of iron in the liver.
The goals of hemochromatosis treatment are to reduce the amount of iron in the body and maintain it at near normal levels, to minimize permanent organ damage, and to address complications. If a person has secondary hemochromatosis, then treatment should also address the underlying disorder or condition. Because not all individuals who have the genetic changes need treatment, only those who have organ damage from excess iron are generally treated.
Hemochromatosis is usually treated with phlebotomy therapy, which typically involves the removal of a unit of blood. The frequency and length of treatment depend on the cause and degree of iron overload; for example, in those with severe iron overload, phlebotomy may initially be done once or twice a week, but after the excess iron is removed, phlebotomy may only be done a few times a year.
There is no cure for hereditary hemochromatosis, but it can be successfully managed over a person’s lifetime.
Someone who has secondary hemochromatosis may not require long-term blood removal treatment if the underlying condition can be resolved–and if their iron overload is due to many transfusions, it may not be possible to do phlebotomy if the need for transfusions is still present. There are also drugs that bind iron and allow it to be eliminated in the urine, (iron chelation drugs) and drugs that reduce gastric acid production (proton pump inhibitors) that reduce the amount of iron in food that is absorbed. These may be used for people who cannot safely have phlebotomy performed.
The U.S. Food and Drug Administration has approved the use of blood from hemochromatosis patients as donor blood. For a list of locations where hemochromatosis patients can go to donate their blood, visit the American Hemochromatosis Society’s web page on this subject.
The HFE Gene
The following lists possible gene combinations for the HFE gene:
- Two copies of C282Y or a copy of C282Y together with a copy of H63D or S65C mutant genes places a person at the highest risk for Hereditary hemochromatosis.
- Two copies of H63D, S65C, or one copy each of H63D and S65C puts a person in the low risk category and is only rarely associated with HH.
- A single copy of C282Y, H63D or S65C means that the person is a carrier. Carriers do not develop the disease, but they can pass it on to their offspring if they have children with someone who is also a carrier.
Of course, other genes besides the HFE gene can affect a person’s ability to metabolize iron, so no combination of genes guarantees that someone will or will not develop the disease. For example, it is estimated that only about 25% of men and about 1% of women who have two copies of the C282Y mutation will ever develop organ damage related to excess iron.
Hereditary hemochromatosis affects more men than women, and symptoms of the disorder emerge at an earlier age for men, typically at about 30 to 50 years old. Two other rare forms of inherited hemochromatosis, neonatal and juvenile hemochromatosis, can cause severe iron overload in children and young adults. These disorders are caused by mutations in a different gene, one called HJV that causes changes in a protein called hemojuvelin that also affects iron metabolism. In fact, a small percentage of cases of HH are due to mutations in genes coding for other proteins that affect iron metabolism, including hemojuvelin as well as transferrin-receptor 2, ferroportin and hepcidin. Tests for these mutations are not widely available, however.
Sources Used in Current Review
Vanclooster, A. et al. Proton pump inhibitors decrease phlebotomy need in HFE hemochromatosis: Double-blind randomized placebo-controlled trial, Gastroenterology. 2017; 152: 678 – 680. http://dx.doi.org/10.1053/j.gastro.2017.06.006
(2017, April 18) Haemochromatosis International. Therapeutic recommendations in HFE haemochromatosis (draft of pre-final document). Available at http://haemochromatosis-international.org/wp-content/uploads/2017/04/Pre-final-Form-17April2017-Therapeutic-recommendations-in-HFE-haemochromatosis.pdf. Accessed on 9/28/17.
(2011, February 1, updated). Explore hemochromatosis: Who is at risk for hemochromatosis? National Heart, Lung, and Blood Institute. Available online at www.nhlbi.nih.gov/health/health-topics/topics/hemo/atrisk. Accessed on 9/28/17.
Allen, K.J., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. New England Journal of Medicine. 2008; 358: 221 – 230. http://dx.doi.org/ 10.1056/NEJMoa073286
Hannuksela, J. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy, Heart Failure. 2005; 7: 103 – 108. http://dx.doi.org/10.1016/j.ejheart.2004.03.007
Sources Used in Previous Reviews
(2012 May). Hemochromatosis. National Digestive Disease Information Clearinghouse [On-line information]. Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/hemochromatosis/index.aspx. Accessed September 2013.
(2010 September). Hemochromatosis (Iron Storage Disease) Training and Education. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/ncbddd/hemochromatosis/training/index.html. Accessed September 12, 2013.
(2011 February). What is Hemochromatosis. National Heart, Lung, and Blood Institute [On-line information]. Available online at http://www.nhlbi.nih.gov/health/dci/Diseases/hemo/hemo_whatis.html. Accessed September 2013.
(2012 October). Is there a test for hereditary hemochromatosis? National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/page.cfm?pageID=10001214. Accessed September 2013.
(February 1, 2011) National Heart, Lung, and Blood Institute. What is Hemachromatosis? Available online at http://www.nhlbi.nih.gov/health/health-topics/topics/hemo/. Accessed September 2013.
Bacon B, et al. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Available online through http://www.aasld.org. Accessed October 2013.
(March 18, 2013) Duchini A. Hemochromatosis. Medscape Reference. Available online at http://emedicine.medscape.com/article/177216-overview. Accessed November 2013.
Clinical Chemistry: Theory, Analysis, and Correlations. Kaplan L, Pesce A, eds. 2nd ed. St. Louis: The C. V. Mosby Company; 1989.
Gastroenterology 1999 Vol 116, p.193-207 (NIH Consensus Conference).
Karl V. Voelkerding, MD, President, Gene Insight, LLC, Madison, Wisconsin.
(2009 February). What is Hemochromatosis. NHLBI [On-line information]. Available online at http://www.nhlbi.nih.gov/health/dci/Diseases/hemo/hemo_whatis.html. Accessed June 2009.
(Updated 2009 April 10). Learning About Hereditary Hemochromatosis. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/page.cfm?pageID=10001214. Accessed June 2009.
Sfeir, H. and Klachko, D. (Updated 2008 July 17). Hemochromatosis. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/177216-overview. Accessed June 2009.
Mayo Clinic Staff (2008 September 12). Hemochromatosis. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/print/hemochromatosis/DS00455/DSECTION=all&METHOD=print. Accessed June 2009.
(2007 April). Hemochromatosis. National Digestive Disease Information Clearinghouse [On-line information]. Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/hemochromatosis/index.htm. Accessed June 2009.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC.
Allen KJ et al. Iron Over-load-Related Disease in HFE Hereditary Hemochromatosis. New England Journal of Medicine January 17 2008, vol 358, Pp 221-230.
Swinkels et al. Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches. Clin Chem 52 (6): 950-968 (2006).